Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report) shares traded up 3.7% during mid-day trading on Monday . The company traded as high as C$1.94 and last traded at C$1.94. 35,330 shares changed hands during trading, a decline of 73% from the average session volume of 129,239 shares. The stock had previously closed at C$1.87.
Medicenna Therapeutics Trading Down 4.2 %
The firm’s 50-day moving average price is C$2.25 and its 200-day moving average price is C$1.51. The company has a market cap of C$137.60 million, a P/E ratio of -8.00 and a beta of 1.29. The company has a quick ratio of 4.65, a current ratio of 5.00 and a debt-to-equity ratio of 0.06.
Medicenna Therapeutics Company Profile
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors.
Read More
- Five stocks we like better than Medicenna Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- This Stock’s Price Shifts Into High Gear With Analyst Upgrades
- What Does Downgrade Mean in Investing?
- AI Boosts Glass Tech Leader Stock: Shares Up 75% and More to Come
- Investing In Preferred Stock vs. Common Stock
- AI Partnership Boosts This Top Tech Stock: Ready for More Gains?
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
